[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-384303-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-384303-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","car-nk-cell-therapy-for-the-treatment-of-metastatic-melanoma-potential-prospects","CAR NK Cell Therapy for the Treatment of Metastatic Melanoma - Potential & Prospects","","Melanoma is among the most lethal cancers, causing 80% of skin cancer deaths while representing only about 5% of cases. Its high heterogeneity drives genetic and epigenetic mechanisms that rapidly enable secondary drug resistance, leaving limited treatment options and making new therapies essential. CAR-T successes in hematologic malignancies are tempered by immune-induced side effects and systemic toxicities. CAR-NK immunotherapies offer a safer alternative with fine-tuned cytotoxic activity. This review outlines melanoma clinical context, NK cell immunobiology, immunosuppressive barriers, and chimeric antigen receptor design, then proposes future CAR-NK engineering innovations to improve efficacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/car-nk-cell-therapy-for-the-treatment-of-metastatic-melanoma-potential-prospects/384303/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/car-nk-cell-therapy-for-the-treatment-of-metastatic-melanoma-potential-prospects/384303.png","ImageObject",300,407,{"name":42,"@type":43},"Well Done","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is metastatic melanoma difficult to treat?","Question",{"text":63,"@type":64},"Melanoma heterogeneity involves genetic and epigenetic mechanisms that enable rapid secondary drug resistance, and increasing metastatic sites reduce treatment effectiveness. Survival remains poor under current options.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limitations do CAR-T therapies have in melanoma treatment?",{"text":68,"@type":64},"CAR-T use is constrained by immune-induced side effects and systemic toxicities, including graft-versus-host disease, immune effector cell-associated neurologic syndrome, and cytokine release syndrome.",{"name":70,"@type":61,"acceptedAnswer":71},"How does CAR-NK cell therapy differ from CAR-T in safety and function?",{"text":72,"@type":64},"CAR-NK immunotherapies are described as promising alternatives because they offer a more favorable safety profile and can provide fine-tuned cytotoxic activity against tumors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},384303,1790385412,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","cells  \nReview  \nCAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects  \nWinston Hibler , Glenn Merlino and Yanlin Yu *  \nCitation: Hibler, W.; Merlino, G.; Yu, Y. CAR NK Cell Therapy for the Treatment of Metastatic Melanoma:  \nPotential & Prospects. Cells 2023, 12, 2750. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cells12232750  \nAcademic Editor: Ritva Tikkanen  \nReceived: 25 October 2023  \nRevised: 22 November 2023  \nAccepted: 26 November 2023  \nPublished: 30 November 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA  \n* [Correspondence: yuy@mail.nih.gov](Correspondence: yuy@mail.nih.gov); Tel.: +1-240-760-6812  \nAbstract: Melanoma is among the most lethal forms of cancer, accounting for 80% of deaths despite comprising just 5% of skin cancer cases. Treatment options remain limited due to the genetic and epigenetic mechanisms associated with melanoma heterogeneity that underlie the rapid development of secondary drug resistance. For this reason, the development of novel treatments remains paramount to the improvement of patient outcomes. Although the advent of chimeric antigen receptor-expressing T (CAR-T) cell immunotherapies has led to many clinical successes for hematological malignancies, these treatments are limited in their utility by their immune-induced side effects and a high risk of systemic toxicities. CAR natural killer (CAR-NK) cell immunotherapies area particularly promising alternative to CAR-T cell immunotherapies, as they offer a more favorable safety profile and have the capacity for fine-tuned cytotoxic activity. In this review, the discussion of the prospects and potential of CAR-NK cell immunotherapies touches upon the clinical contexts of melanoma, the immunobiology of NK cells, the immunosuppressive barriers preventing endogenous immune cells from eliminating tumors, and the structure and design of chimeric antigen receptors, then finishes with a series of proposed design innovations that could improve the efficacy CAR-NK cell immunotherapies in future studies.  \nKeywords: natural killer cell; CAR-NK cell; melanoma; metastasis; CAR-NK cell therapy; cancer immunotherapy  \n1. Introduction  \nMelanoma, arising from the malignant transformation of melanocytes, is an aggressive and potentially lethal form of skin cancer. It is often caused by solar UV radiation, but there are myriad other environmental, immunological, and genetic risk factors that can also contribute to an individual's predisposition towards melanoma [1,2] . For instance, heritable mutations such as in MC1R, CDK4, and CDKN2A, as well as genetic conditions like xeroderma pigmentosum (XP), have all been associated with an increased risk of melanoma development [3] . Melanoma is one of three major skin cancers, the other two being squamous cell carcinoma and basal cell carcinoma. Though melanoma accounts for only 5% of new skin cancer cases, it is ultimately responsible for approximately 80% of skin cancer deaths [4] . The incidence and mortality rates for malignant melanoma have steadily increased over the past few decades, particularly amongst older patients, whereas survival rates have remained relatively constant [4,5] .  \nResistance to a broad spectrum of therapies presents an ongoing challenge for the treatment of melanoma. Melanoma mutations occur at an exceptionally high rate, in turn driving the rapid development of treatment resistance [6] . Chemotherapeutics are often ineffective treatments for melanoma: standa","cbCaii8LZewRBsZL","https://ap.wps.com/l/cbCaii8LZewRBsZL","pdf",2154924,31,"English","# Introduction\n## Melanoma biology and risk factors\n## Treatment resistance and metastatic progression\n# CAR-T limitations and rationale for CAR-NK therapy\n# NK cell immunobiology and immunosuppressive barriers\n# Chimeric antigen receptor structure and design\n# Design innovations to improve CAR-NK efficacy","[{\"question\":\"Why is metastatic melanoma difficult to treat?\",\"answer\":\"Melanoma heterogeneity involves genetic and epigenetic mechanisms that enable rapid secondary drug resistance, and increasing metastatic sites reduce treatment effectiveness. Survival remains poor under current options.\"},{\"question\":\"What limitations do CAR-T therapies have in melanoma treatment?\",\"answer\":\"CAR-T use is constrained by immune-induced side effects and systemic toxicities, including graft-versus-host disease, immune effector cell-associated neurologic syndrome, and cytokine release syndrome.\"},{\"question\":\"How does CAR-NK cell therapy differ from CAR-T in safety and function?\",\"answer\":\"CAR-NK immunotherapies are described as promising alternatives because they offer a more favorable safety profile and can provide fine-tuned cytotoxic activity against tumors.\"}]","CAR NK Cell Therapy for the Treatment of Metastatic Melanoma - Potential & Prospects | PDF",1790262098,78]